Roche Foundation Medicine is pleased to announce the launch of FoundationOne®Liquid, our new second-generation liquid biopsy test for patients with solid tumours.56

Granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) in April 2018, FoundationOne®Liquid builds on the technology of FoundationACT® and now includes more than 70 genes and genomic biomarkers for microsatellite instability (MSI).56

 

Maintaining its clinically practical single blood draw of two tubes of blood sampling method, FoundationOne®Liquid aims to be the first FDA-approved liquid biopsy assay to incorporate multiple companion diagnostics (CDx) and multiple biomarkers to inform the use of targeted oncology therapies, including immunotherapies.56,57

Single blood draw of two tubes of blood56,57

FoundationOne®Liquid detects the four main classes of genomic alterations and reports MSI High56,57

A clear, in-depth report supports your clinical decision making56,57

The planned launch of FoundationOne®Liquid globally is this year and will be available to order for your patients soon so kindly watch this space.
 

For more information, please contact your local Roche Foundation Medicine Customer Service team by clicking here. Alternatively, you can reach us at APAC.foundation@roche.com.

FoundationOne®Liquid FAQs

  • DOES THE FOUNDATIONONE®LIQUID CTDNA ASSAY APPLY TO ALL TYPES OF CANCER?

    FoundationOne®Liquid can help deliver meaningful molecular insights across a range of solid tumour types, including but not limited to: Lung,25,28 Breast,29,30 Gastrointestinal31 and Prostate Cancer.32

  • WHO IS ELIGIBLE FOR A FOUNDATIONONE®LIQUID PROFILE?

    FoundationOne® is our flagship profile for patients with solid tumours. However, in cases where Comprehensive Genomic Profiling (CGP) with FoundationOne® is not possible or feasible, the patient may be eligible for profiling with FoundationOne®Liquid.

  • WHEN MAY FOUNDATIONONE®LIQUID BE USED IN PLACE OF FOUNDATIONONE®?

    FoundationOne®Liquid is an alternative profiling method to FoundationOne® in cases where there is insufficient or inadequate tissue from a recent biopsy,23 or where repeat analyses have led to tissue exhaustion precluding subsequent testing.33

     

    In other instances, procedural limitations can be the prohibiting factor, such as when direct biopsy is technically difficult to obtain,23 or when progression or recurrence is suspected and a repeat biopsy is not feasible.33

     

  • WHAT IS CIRCULATING TUMOUR DNA (ctDNA) AND WHY IS IT USEFUL?

    Sometimes patient factors can determine the need for profiling with FoundationOne®Liquid, for example, if tissue biopsy poses an unacceptable risk to the patient,22,23 or the patient refuses a tissue biopsy.

  • IS CTDNA DIFFICULT TO DETECT?

    Detecting ctDNA can be challenging.23, 36 Circulating cell‑free DNA (cfDNA) is highly fragmented, present at very low concentrations, and contains only a small fraction of tumour‑derived ctDNA (often <1.0% of total cfDNA).22,33,35,36 Not all tumours shed DNA into blood stream, so ctDNA may not be detected in all patients. The level of ctDNA is also known to vary considerably (between 0.01% to 90%),33,37 depending on tumour type, tumour stage, and a range of other factors, including rate of release, physiological factors (e.g. renal function) and time of blood draw.22,33,37‑42

     

    As a result, the isolation and identification of ctDNA require ultrasensitive analytical analysis.22,36

     

We have even more to offer - learn about our other profiles: